1,117 results on '"Copelan, Edward A."'
Search Results
202. Peripheral Immune Profile and Minimal Residual Disease (MRD) Burden Following Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM)
203. Enhanced Support Services Including Nurse Navigation Mitigate Socioeconomic Disparities in the Treatment of Patients with Acute Lymphoblastic Leukemia
204. MYC Pathway Upregulation Identified in Non-Responders to Hypomethylating Agents and Presents a Therapeutic Target in Acute Myeloid Leukemia
205. Neighborhood Disadvantage Is Associated with Inferior Overall Survival for Acute Myeloid Leukemia Patients Treated with Standard Intensive Induction
206. Precision (in Language and) Medicine
207. Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
208. Filgrastim Plus Fixed-Dose Plerixafor is Cost-Effective in Peripheral Blood Hematopoietic Cell Mobilization in Patients with Multiple Myeloma
209. Increasing Use of Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients Age 70 Years and Older: A CIBMTR Study of Trends and Outcomes
210. Low Incidence of Hemolysis, Delayed Red Cell Engraftment and Pure Red Cell Aplasia with Post Transplantation Cyclophosphamide following ABO Mismatched Non-Myeloablative Haploidentical Peripheral Blood Stem Cell Transplantation
211. Peripheral Blood Progenitor Cell Mobilization in Patients with Multiple Myeloma Utilizing a Reduced Fixed Dose of Plerixafor and a Unique Mobilization Algorithm is Feasible and Maximizes Day 1 Collection Yield
212. Cytomegalovirus Infection in T Cell Replete Peripheral Blood Stem Cell Transplant with Post-Transplant Cyclophosphamide- A Single Center Experience
213. Identification and Validation of IMiD-14 Model Predictive of IMiD Resistance in Multiple Myeloma
214. Impact of Lenalidomide Maintenance Therapy on Immune Polarization and Activation in Multiple Myeloma
215. Distribution of Cytogenetic Abnormalities in African American Multiple Myeloma Patients May be Unique for Different Geographic Regions
216. 569 - Use of Isavuconazole for Prophylaxis Against Invasive Fungal Infections in Allogeneic Stem Cell Transplant Patients: A Real World Experience
217. 106 - Survival Trends after Allogeneic Hematopoietic Cell Transplant (HCT) in Children Less Than One-Year-Old (Infants)
218. Neutropenic fever during peripheral blood progenitor cell mobilization is associated with decreased CD34+ cell collection and increased apheresis collection days.
219. Successful Hematopoietic Stem Cell Transplantation Following a Cyclophosphamide-Containing Preparative Regimen with Concomitant Phenobarbital Administration
220. Tacrolimus Pharmacogenetics and Steady State Drug Concentrations in Cancer Patients Undergoing Allogeneic Stem Cell Transplantation
221. Effect of Immunomodulatory Drugs (IMiDs) on Immune Effectors after Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma
222. Validation of Dynamic Biomarker-Based Risk Progression Model for Smoldering Multiple Myeloma
223. Long-term survival after high-dose chemotherapy with autologous hematopoietic cell transplantation in metastatic breast cancer
224. HSCT: navigating the journey ahead
225. Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation
226. Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Lingering Uncertainties and Emerging Possibilities
227. Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes
228. Prognostic Impact of a Modified European LeukemiaNet (ELN) Genetic Risk Stratification in Predicting Outcomes for Adults with Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HCT). a Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis for the CIBMTR Acute Leukemia Writing Committee
229. Bortezomib + MEC (Mitoxantrone, Etoposide, Cytarabine) for Relapsed/ Refractory Acute Myeloid Leukemia: Final Results of an Expanded Phase 1 Trial
230. Impact of Day 28 Absolute Lymphocyte Count on Outcome of Adult Patients with Acute Myeloid Leukemia
231. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA‐identical sibling donor allogeneic hematopoietic cell transplantation
232. Sibling versus Unrelated Donor Allogeneic Hematopoietic Cell Transplantation for CML: Refined HLA-matching shows more GVHD but not less relapse
233. Vitamin D Level after Allogeneic Hematopoietic Stem Cell Transplant
234. 84 - Impact of Higher-Dose Total Body Irradiation Conditioning on Outcome of an Allogeneic Hematopoietic Cell Transplant (HCT) in the Modern Era
235. Self-Reported Distress Is Associated with Decreased Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia
236. Clonal Hematopoiesis Prevalence and Mutational Spectrum in Patients with Plasma Cell Disorders at the Time of Diagnosis and Its Impact on Clinical Features, Cardiovascular Complications, and Survival
237. Prevention of Severe GVHD Employing Cyclosporine in HLA-Matched Marrow Transplant for Leukemia
238. CAR T-Cell Therapy in Non-Hodgkin Lymphoma Patients.
239. Chronic Myelogenous Leukemia
240. SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia
241. Should busulfan now be part of the standard treatment for patients with acute myeloid leukemia?
242. Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations
243. Risk for Developing Myelodysplastic Syndromes in Prostate Cancer Patients Definitively Treated With Radiation
244. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI
245. Providing Personalized Prognostic Information for Adult Leukemia Survivors
246. Sibling versus Unrelated Donor Allogeneic Hematopoietic Cell Transplantation for Chronic Myelogenous Leukemia: Refined HLA Matching Reveals More Graft-versus-Host Disease but not Less Relapse
247. Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International Blood and Marrow Transplantation Research
248. SWOG S0919: A phase II study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukemia (AML).
249. Impact of allogeneic hematopoietic stem cell transplant (HSCT) on patients harboring the spliceosome mutation SRSF2.
250. Allogeneic Hematopoietic Cell Transplantation for Fanconi Anemia in Patients With Pretransplantation Cytogenetic Abnormalities, Myelodysplastic Syndrome, or Acute Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.